Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020
10 août 2020 16h05 HE
|
MyoKardia, Inc.
BRISBANE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial...
MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
05 août 2020 16h05 HE
|
MyoKardia, Inc.
BRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare...
MyoKardia Reports Second Quarter 2020 Financial Results
04 août 2020 16h05 HE
|
MyoKardia, Inc.
BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one...
CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
03 août 2020 09h52 HE
|
MyoKardia, Inc.
BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey...
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
03 août 2020 08h30 HE
|
MyoKardia, Inc.
BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll...
MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020
28 juil. 2020 08h00 HE
|
MyoKardia, Inc.
BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020....
MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy
23 juil. 2020 16h05 HE
|
MyoKardia, Inc.
BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to...
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
21 juil. 2020 07h30 HE
|
MyoKardia, Inc.
BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for...
MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary
06 juil. 2020 08h00 HE
|
MyoKardia, Inc.
BRISBANE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins...
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
22 juin 2020 08h00 HE
|
MyoKardia, Inc.
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New...